<DOC>
	<DOCNO>NCT00507169</DOCNO>
	<brief_summary>The study examine dose SVT-40776 best term efficacy , safety tolerability compare placebo tolterodine</brief_summary>
	<brief_title>SVT-40776 Patients Suffering From Overactive Bladder Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Patients suffer OAB least 6 month prior inclusion Pregnant breastfeed woman Any medical condition need comedication interfere drug investigation ( SVT40776 ) comparator ( tolterodine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>